Sign in Subscribe

Latest

The Regulator Just Moved the Map

The Regulator Just Moved the Map

This week, the regulator wrote the script. FDA opened the door on AI-monitored real-time clinical trials with named pharma collaborators. Science published peer-reviewed evidence of physician-level LLM reasoning. OpenEvidence, reportedly used by 40% of US physicians, pulled its product from the EU and UK over AI Act uncertainty. Pharma extended

The Carrot and the Stick Arrived Together

The Carrot and the Stick Arrived Together

While many still chased ambient AI headlines, the FDA, CMS, and a half-dozen state regulators continued to write the rules that determine which AI gets paid for, which gets enforced against, and which gets pulled. Procurement committees will now have a different rubric to use. Health systems already operating at

AI is On the Path to Becoming a Regulated Category.

AI is On the Path to Becoming a Regulated Category.

This week the regulatory scaffolding for American healthcare AI arrived in a single five-day stretch. NCCN embedded an AI-derived risk threshold in cancer screening guidelines. FDA validated its first AI drug development tool. CMS wrote a national reimbursement pathway for a specific AI model. HSCC, IMDRF, ACCME, and five state

The New Rules of Healthcare AI Are Here: Reimbursement, Regulation, and Real Proof

The New Rules of Healthcare AI Are Here: Reimbursement, Regulation, and Real Proof

This week the healthcare AI landscape crossed a threshold. CMS created a reimbursement code for AI-detected coronary calcium. The FDA signaled it is moving toward post-market oversight. Four states advanced therapy chatbot bans. The WISeR Medicare pilot launched AI-powered claims review. And Q1 digital health funding hit a record $4

The proof era has arrived: AI claims are now being tested like drugs, and health systems are paying attention.

The proof era has arrived: AI claims are now being tested like drugs, and health systems are paying attention.

This week it looks as if the era of vendor-led proof points is ending. Peer-reviewed trials, multicenter studies, and scale decisions driven by documented outcomes are replacing the pilot press release. Procurement committees now have evidence to demand. Health systems that already deployed are separating from those still evaluating. JAMA

The Agent Threshold: AI Is No Longer Assisting... It's Acting

The Agent Threshold: AI Is No Longer Assisting... It's Acting

AI agents aren't waiting for permission anymore. They're coordinating cancer pathways, renewing prescriptions, and routing patients through Amazon's app. This week's signals reveal where the real infrastructure of healthcare AI is being built — and by whom. The leaders gaining ground aren'

Healthcare AI’s Next Constraint: Federal Momentum, State Friction

Healthcare AI’s Next Constraint: Federal Momentum, State Friction

March 24th, 2026 Healthcare AI is still deep in its announcement era. Every week brings more copilots, agents, platforms, studies, and funding rounds. But the real challenge for healthcare leaders is not keeping up with the volume. It is identifying which developments actually change how healthcare can operate. Strategic Exercise

Healthcare AI is Entering a New Phase. Governance Becomes the New Scale Advantage

Healthcare AI is Entering a New Phase. Governance Becomes the New Scale Advantage

The biggest signal this week was not another flashy launch. It was the market-wide shift from AI experimentation to governed deployment. March 17th, 2026 Strategic Exercise for Healthcare Leaders Copy this newsletter into ChatGPT or Claude along with your 2026 strategy and ask: “Based on these Healthcare AI signals from